![From QSR to QMSR: Meeting FDA’s New Requirements From QSR to QMSR: Meeting FDA’s New Requirements](https://www.fdanews.com/ext/resources/Book-Covers-NEW/From-QSR-to-QMSR-500.png?height=200&t=1714569011&width=200)
Home » Medivation Brushes Off Sanofi’s $9.3B Offer
Medivation Brushes Off Sanofi’s $9.3B Offer
![Sanofi-logo.gif](https://www.fdanews.com/ext/resources/test/Drug-Images/Sanofi-logo.gif?t=1604968321&width=430)
May 5, 2016
A day after Sanofi made its $9.3 billion hostile takeover bid for Medivation, the company’s board unanimously shot it down.
Medivation CEO David Hung called Sanofi’s bid “opportunistically-timed” and “substantially inadequate” stressing that it “substantially” undervalued the company’s unique oncology franchise.
Medivation’s statement also appealed directly to shareholders — whom Sanofi is targeting with its bid — claiming that the board’s business plan “will deliver value to its stockholders that is far superior to Sanofi’s proposal.”
Upcoming Events
-
21Oct